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Background: The aim of the present study was to identify the long-term major adverse cardiovascular events
(MACE) in adult congenital heart disease (ConHD) patients in Taiwan.
Methods: From the National Health Insurance Research Database (1997-2010), adult patients (≥18 years) with
ConHD were identified and compared to non-ConHD control patients. The primary end point was the incidence of
MACE. Cox proportional hazards models were used to compute hazard ratios as estimates for multivariate adjusted
relative risks with or without adjusting for age and sex.
Results: A total of 3,267 adult patients with ConHD were identified between 2000 and 2003 with a median follow-up
of 11 years till December 31, 2010. The five most common types of ConHD were atrial septal defects, ventricular septal
defects, patent ductus arteriosus, tetralogy of Fallot, and pulmonary stenosis. Overall, the incidence of MACE was
4.0-fold higher in the ConHD group compared with the controls. After adjustment for age and gender, the patients
with ConHD had an increased risk of heart failure, malignant dysrhythmia, acute coronary syndrome, and stroke. The
adult ConHD patients had a decreased life-long risk of MACE if they received surgical correction, especially in the
patients with atrial septal defects.
Conclusions: After a median of 11 years of follow-up, the Taiwanese patients with ConHD were at an increased
risk of life-long cardiovascular MACE, including heart failure, stroke, acute coronary syndrome, and malignant
dysrhythmia. Surgical correction may help to decrease long-term MACE in ConHD patients, especially those with ASD.Background
Congenital heart disease (ConHD) is the most common
congenital disorder in newborns and can remain a com-
plication throughout life [1]. The prevalence of ConHD
is approximately 2.5–53.2 per 1000 live births worldwide
and 13.8 per 1000 live births in Taiwan [2]. Infant mor-
tality is approximately 10%–20% in the first year [3],
however early detection and surgical correction can im-
prove the overall survival and quality of life [4]. Since
1987, the mean life expectancy of adult patients with
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reproduction in any medium, provided the orindividuals, although it has gradually increased from
less than 40 years to more than 50 years of age [5,6].
The most commonly reported major cardiovascular
adverse events (MACE) include myocardial infarction,
heart failure, percutaneous cardiac intervention, cor-
onary artery bypass grafting, malignant dysrhythmia,
cardiac shock, implantable cardiac defibrillator, malig-
nant dysrhythmia and death [7,8].
Most reports on adult patients with ConHD have been
on Western [9,10] rather than Asian populations [11].
Therefore, the aim of the current study was to clarify
the complications associated with long-term MACE in
adult Asian patients with ConHD.
Methods
Data source and the study cohort
This is a nationwide population-based retrospective cohort
study using the claims database of the National Health. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Lin et al. BMC Cardiovascular Disorders 2014, 14:38 Page 2 of 8
http://www.biomedcentral.com/1471-2261/14/38Insurance Research Database (NHIRD) (http://nhird.nhri.
org.tw/date_01.html) from 1997-2010 in Taiwan. Cur-
rently, the National Health Insurance program covers
more than 99% of the population of Taiwan [12], and the
NHIRD provides medical claims, registration, and reim-
bursement data [7,8].
By regulation, all patients with major diseases including
the ConHD should be registered into the Registry of Cata-
strophic Illness Patients (HV) database, (http://nhird.nhri.
org.tw/date_01.html). During 2000-2003, 3,267 adult pa-
tients (aged ≥18 years) with ConHD (the exposed cohort)
were identified from the HV database and followed up till
December 31, 2010. The patients with a first MACE before
ConHD was diagnosed, and the patients without age and
gender information were excluded (Figure 1, left side).
Diagnostic information was based on the International
Classification of Diseases, Ninth Revision, Clinical Modifi-
cation (ICD-9-CM). The patients with ConHD were de-
fined as those having completed three or more outpatient
verification visits within one year, or those who had been
hospitalized with a diagnosis of ConHD between 2000 and
2003. A diagnosis of ConHD included cyanotic ConHD
(tetralogy of Fallot, TOF: ICD-9 745.2; common truncus,
CT: ICD-9 745.0; double outlet right ventricle: ICD-9
745.11; or other cyanotic ConHD: ICD-9 745.1, 745.12,
745.3, 746.1, 746.7, 747.41) and non-cyanotic ConHD (ven-
tricular septal defect, VSD: ICD-9 745.4; ostium or secun-
dum type atrial septal defect, ASD: ICD-9 745.5; patent
ductus arteriosus, PDA: ICD-9 747.0; congenital stenosis of
pulmonary valve, PS: ICD-9 746.02; or other non-cyanotic
ConHD: 745.60, 745.6, 746.2, 746.3, 746.82, 747.1).
The comparison cohort consisted of adults (aged
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Figure 1 Flow chart of the study.in the Registry of Catastrophic Illness Patients and not
diagnosed with a previous MACE at baseline. This con-
trol group was randomly selected from the Longitudinal
Health Insurance Database (LHID), a subset of the
NHIRD containing all original claims data of one million
randomly sampled insured patients in 2000 (http://
nhird.nhri.org.tw/date_01.html). All non-ConHD sub-
jects were matched with the study cohort for age, sex,
and residential area. Details were described in the right
of the flow chart (Figure 1, right site).
We also prospectively evaluated whether surgical
intervention reduced the occurrence of MACE by com-
paring ConHD patients with and without surgical treat-
ment. We identified those who underwent surgical
treatment by the presence of ICD-9-CM procedure
codes during follow-up as the followings: 3551, 3552,
3561, 3571 for ASD; 3553, 3562, 3572 for VSD; 3885 for
PDA; 3581, 3582 for TOF; and 3596 for PS. Informed
consent was waived as the database analysis used de-
identified secondary data, and the study was approved
by the Institutional Review Board of Chang Gung Me-
morial Hospital (#101-0400B).
Identification of MACE cases
The primary outcome of this study was newly diagnosed
MACE during the study period. Newly diagnosed cases
of MACE were identified as those with 3 or more visits
to outpatient care clinics within one year or those hospital-
ized with a diagnosis of MACE (acute coronary syndrome:
ICD-9 410-410.9, or ICD-9 36.0-36.03, 36.05-36.09,
36.1-36.99, V45.81; heart failure: ICD-9 428.0-428.10;
cerebrovascular accident, stroke: ICD-9 430-432, 433-437;
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[7,8].
Statistical analysis
Group characteristics at baseline were compared using
χ2 tests. The person-time for each participant was calcu-
lated from January 1, 2000 or the date of confirmed
ConHD during 2000-2003 to the date of any type of
MACE, death, insurance discontinuation, or December
31, 2010, whichever came first. Cox proportional hazards
models were used to estimate hazard ratios (HR) and
95% confidence intervals (95% CI) for incident MACE,
adjusting for age and sex. The assumption of propor-
tional hazards was checked by including the interaction
between covariates and the logarithm of time in the
model. If variables other than the primary variables of
interest did not satisfy the proportional hazards assump-
tion, we included the time-interaction terms for these
variables in the model. The results of the analysis in the
models with and without the time-interaction terms
were essentially the same; therefore, we did not include
the time-interaction terms in the models presented here.
Age and sex adjusted survival curves were generated
from the Cox proportional hazards models. A p value
less than 0.05 was considered to be statistically signifi-
cant. Statistical analyses were performed using SAS soft-
ware (version 9.2; SAS institute Inc., Cary, NC, USA).
Results
The characteristics of the study population are shown in
Table 1. A total of 3,267 subjects with a clinical diagno-
sis of ConHD and 6,534 subjects without ConHD were
included in this study. The patients with ConHD had a
mean age of 36.5 ± 14.6 years, and the non-ConHDTable 1 Baseline characteristics
Variables ConHD (N = 3267) non-ConHD (N = 6534)
n (%) n (%)
Gender
Female 2035 (62.3) 4070 (62.3)
Male 1232 (37.7) 2464 (37.7)
Age (years)
18-40 2058 (63.0) 4116 (63.0)
≥40 1209 (37.0) 2418 (37.0)
Residential area
Northern 1589 (48.6) 3187 (48.8)
Central 790 (24.2) 1579 (24.2)
Southern 831 (25.5) 1656 (25.4)
Eastern 53 (1.6) 106 (1.6)
Island 3 (0.1) 6 (0.1)
ConHD, congenital heart disease; n, number of subjects; N, total number
of subjects.subjects had a mean age of 36.7 ± 14.8 years. There were
no significant differences in age, sex, or residential area
between the two groups.
In the study cohort of 3,267 ConHD patients who
were identified from 2000 to 2003 without any docu-
mented history of MACE, the five most prevalent lesions
were ASD (n = 1,361), VSD (n = 1,147), PDA (n = 314),
TOF (n = 232), and PS (n = 85) (Figure 2). There were
1,148 occurrences of MACE over the 11-year follow-up
period. During the course of 26,372 person-years of
follow-up in the ConHD cohort, 795 new cases of
MACE were diagnosed. Over 75% ConHD cohort re-
ceived surgical correction during the first one and half
year follow-up time. Due to possible perioperative risk
bias, we excluded the ConHD cohort patients who had
MACE within one and half years after surgery. During
the course of 26,184 person-years of follow-up in the
ConHD cohort, 487 new cases of MACE were diagnosed
(Table 2). The crude incidence of 18.2 cases per 1000
person-years was 3.6 times higher than the incidence in
the non-ConHD group (5.0 cases per 1000 person-
years). After adjusting for age and sex, the risk of MACE
was increased in the patients with ConHD (adjusted HR,
4.0; 95% CI, 3.5-4.6 p < 0.0001) compared with those
without ConHD (Table 2).
To evaluate the risks of various incident cases of
MACE, we analyzed different MACE outcomes in separ-
ate models (Table 2 and Figure 3). The patients with
ConHD were much more likely to develop HF than the
subjects without ConHD (adjusted HR, 13.2; 95% CI,
10.1-17.2; p < 0.0001). The risk of developing MD was
significantly higher in the subjects with ConHD than in
those without ConHD (adjusted HR, 12.6; 95% CI, 6.2-
25.7; p < 0.0001). The adjusted HR for ACS was 2.9
times (95% CI, 2.1-4.1; p < 0.0001) higher for the subjects
with ConHD than for those without ConHD. The risk ofFigure 2 The five most prevalent lesions of congenital heart
disease. TOF, teratology of Fallot; ASD, ostium or secundum type
atrial septal defect; VSD, ventricular septal defect; PDA, patent ductus
arteriosus; PS, congenital stenosis of the pulmonary valve.
Table 2 Hazard ratios for incident MACE adjusted for age and sex, according to early and late study periods among
ConHD patients as compared with those without ConHD
Event ConHD non-ConHD Follow-up time
n/N n/N ≥ 1.5 years 1.5 to 4 years ≥ 4 years
Adjusted HR (95% CI) P value Adjusted HR (95% CI) P value Adjusted HR (95% CI) P value
MACE 487/2919 336/6398 4.02 (3.49, 4.62) <.0001 5.50 (4.32, 7.01) <.0001 3.37 (2.83, 4.02) <.0001
ACS 72/3181 61/6413 2.89 (2.05, 4.07) <.0001 7.76 (3.56, 16.93) <.0001 2.06 (1.37, 3.10) 0.0005
HF 337/3014 65/6412 13.20 (10.11, 17.23) <.0001 21.44 (12.60, 36.48) <.0001 10.61 (7.76, 14.51) <.0001
Stroke 214/3166 242/6402 2.16 (1.79, 2.60) <.0001 2.39 (1.72, 3.31) <.0001 2.06 (1.64, 2.58) <.0001
MD 48/3203 9/6412 12.57 (6.15, 25.69) <.0001 - -
MACE, major adverse cardiovascular events; ConHD, congenital heart disease; ACS, acute coronary syndrome; HF, heart failure; MD, malignant dysrhythmia; N = total
number of subjects; n = number of subjects with various; MACE; Adjusted HR (95% CI), hazard ratio for various incident MACEs (95% confidence interval) adjusted for
age and sex.
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0.0001) higher for the subjects with ConHD than for
those without ConHD.
In the ConHD cohort, those with cyanotic ConHD, espe-
cially TOF, were associated with a significantly increased
risk of MACE (adjusted HR, 11.2; 95% CI, 8.0-15.3; p <
0.0001) compared with those without ConHD patients
(Table 3) and 2.9 times higher risk than non-cyanotic
ConHD patients. In those non-cyanotic ConHD patients,
VSD (adjusted HR, 3.5; 95% CI 2.9-4.3; p < 0.0001), ASD
(adjusted HR, 3.7; 95% CI 3.1-4.4; p < 0.0001) and PDA
(adjusted HR, 5.9; 95% CI 4.4-8.0; p < 0.0001) have higher
MACE risk than those without ConHD and the signifi-
cance persisted even after Bonferroni correction.
In the ConHD patients, the adjusted HR for incident
MACE in those with a history of surgery versus thoseFigure 3 Cox survival curves adjusted for age and sex of different con
and half year of follow-up. ASD, ostium or secundum type atrial septal defe
congenital stenosis of pulmonary valve; REF, reference cohort.with no history of surgery was 0.5 (95% CI, 0.4-0.6; p <
0.0001) (Table 4 and Figure 4). A strong negative associ-
ation was observed between a history of surgery in the
ASD patients and the risk of incident MACE (adjusted
HR, 0.3; 95% CI, 0.3-0.5; p < 0.0001) (Table 4). Although
there is a consistent trend of decreasing risk of incident
MACE, no statistically significant differences were found
in the patients with TOF, VSD, and PDA and a history of
surgery after Bonferroni correction (Table 4).
Discussion
The results of this long-term population study showed
that the adult ConHD patients had a much higher risk
of MACE. The prevalence of ConHD in live-births was
similar to those previously reported [13], and the most
common types of ConHD were VSD, ASD, PDA, TOFgenital heart diseases vs. reference cohort. Time = 0, time at one
ct; VSD, ventricular septal defect; PDA, patent ductus arteriosus; PS,
Table 3 Hazard ratios for incident MACE adjusted for age and sex, according to early and late study periods, and
ConHD status






P value Adjusted HR
(95% CI)
P value Adjusted HR
(95% CI)
P value
ConHD 487/2919 16.7% 26184.1 4.02 (3.49, 4.62) <.0001 5.50 (4.32, 7.01) <.0001 3.37 (2.83, 4.02) <.0001
1.Cyanotic 52/236 22.0% 2058.8 10.30 (7.61, 13.94) <.0001 15.12 (9.62, 23.78) <.0001 7.88 (5.19, 11.95) <.0001
TOF 44/191 23.0% 1678.5 11.07 (7.99, 15.33) <.0001 18.94 (11.82, 30.35) <.0001 7.46 (4.68, 11.91) <.0001
CT 4/21 19.0% 182.7 - - -
DORV 1/6 16.7% 52.5 - - -
Other Cyanotic 3/18 16.7% 145.0 - - -
2. Non-Cyanotic 435/2683 16.2% 24125.4 3.80 (3.30, 4.39) <.0001 5.14 (4.01, 6.59) <.0001 3.22 (2.69, 3.86) <.0001
VSD 136/1040 13.1% 9750.6 3.54 (2.89, 4.34) <.0001 3.91 (2.75, 5.56) <.0001 3.38 (2.63, 4.33) <.0001
ASD 211/1223 17.3% 10734.0 3.73 (3.13, 4.44) <.0001 5.17 (3.88, 6.88) <.0001 3.07 (2.45, 3.85) <.0001
PDA 54/275 19.6% 2393.7 5.93 (4.41, 7.96) <.0001 9.87 (6.53, 14.94) <.0001 3.82 (2.45, 5.95) <.0001
PS 4/34 11.8% 317.7 - - -
Other Non
Cyanotic
30/112 26.8% 940.4 - - -
MACE, major adverse cardiovascular events; ConHD, congenital heart disease; Cyanotic, cyanotic congenital heart disease; TOF, Tetrtology of fallot; CT, common
truncus; DORV, double outlet right ventricle; Non-cyanotic, non-cyanotic congenital heart disease; VSD, ventricular septal defect; ASD, ostium or secundum type
atrial septal defect; PDA, patent ductus arteriosus; PS, congenital stenosis of pulmonary valve. n, number of subjects with MACE; N, total number of subjects;
Adjusted HR (95% CI), hazard ratio for incident MACE (95% confidence interval) adjusted for age and sex. All hazard ratios were comapred to reference
cohort (N = 6,398). When the number of incidenct MACE was small (n < 40) in ConHD subgroup, the hazard ratio would not be estiamted by two follow-up
period (the first 1.5 to 4 years, and after the fourth years).
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tality of up to 25-100-fold in a group of adults with
ConHD despite surgical correction [14,15]. In the
current study, we found a higher risk of MACE (up to a
4.0-fold increase) in Taiwanese adults with ConHD than
those without ConHD.
In the current study, heart failure, malignant dysrhyth-
mia, stroke, and acute coronary syndrome were the most
common types of MACE in the ConHD group (Table 2).
When adjusted for sex and age, the overall HR was the
highest in the patients with heart failure, followed byTable 4 Hazard ratios of incident MACE adjusted for age and
patients with and without surgery history
Surgery non-Surgey Follow-up time: ≥1.5 years
n/N n/N Adjusted HR (95% CI) P valu
ConHD 114/1124 309/1486 0.47 (0.38, 0.58) <.000
1.Cyanotic 6/62 35/151 0.34 (0.14, 0.81) 0.015
TOF 3/29 32/144 0.42 (0.13, 1.37) 0.149
2.Non-Cyanotic 108/1062 274/1335 0.48 (0.39, 0.61) <.000
VSD 18/237 99/694 0.55 (0.33, 0.92) 0.021
ASD 62/624 125/463 0.34 (0.25, 0.46) <.000
PDA 19/125 26/114 0.68 (0.37, 1.25) 0.211
MACE, major adverse cardiovascular events; ConHD, congenital heart disease; Cyan
non-cyanotic congenital heart disease; VSD, ventricular septal defect; ASD, ostium o
stenosis of pulmonary valve. n, number of subjects with MACE; N, total number of sub
interval) adjusted for age and sex.those with malignant dysrhythmia and acute coronary
syndrome. This is similar to the studies in Western
countries which reported that the major MACE in adult
patients with ConHD were heart failure, malignant dys-
rhythmia, and stroke.
However, the high risk of acute coronary syndrome in
the adult ConHD patients in the current study is different
from the previous reports. Pillutla et al reported a high
rate of myocardial infarction-related mortality in non-
cyanotic adult congenital heart disease in the US after
2000, and concluded that this might be due to the naturalsex for early and late study periods in various ConHD
Follow-up time: 1.5 to 3 years Follow-up time: Over 3 years
e Adjusted HR (95% CI) P value Adjusted HR (95% CI) P value
1 0.39 (0.28, 0.56) <.0001 0.52 (0.40, 0.69) <.0001
0.28 (0.06, 1.22) 0.091 0.38 (0.13, 1.12) 0.08
0.67 (0.15, 3.00) 0.598 0.24 (0.03, 1.79) 0.164
1 0.40 (0.28, 0.58) <.0001 0.55 (0.41, 0.73) <.0001
0.24 (0.08, 0.79) 0.019 0.74 (0.42, 1.31) 0.298
1 0.27 (0.17, 0.43) <.0001 0.41 (0.27, 0.61) <.0001
0.82 (0.36, 1.88) 0.643 0.55 (0.22, 1.34) 0.185
otic, cyanotic congenital heart disease; TOF, Tetrtology of fallot; Non-cyanotic,
r secundum type atrial septal defect; PDA, patent ductus arteriosus; PS, congenital
jects; Adjusted HR (95% CI), hazard ratio for incident MACE (95% confidence
Figure 4 Cox survival curves adjusted for age and sex with surgery (solid line) and without surgery (dashed line) of congenital heart
diseases patients. Time = 0, time at one and half year of follow-up. (A) Overall congenital heart diseases; (B) Cyanotic congenital heart diseases;
(C) Noncyanotic congenital heart diseases; (D) ventricular septal defect; (E) ostium or secundum type atrial septal defect.
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coronary syndrome is an important MACE in the adult
ConHD among Taiwanese population, and confirmed ahigher risk of acute coronary syndrome compared with
age-matched controls. This result may reflect an ethnic
difference and requires clarification in future studies.
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important and common MACE [2], however our find-
ings suggest that the most common and persistent
MACE is heart failure. Some possible reasons to explain
this have been proposed, including sequelae associated
with long-time pressure or volume overload after surgi-
cal correction and malignant dysrhythmia (e.g., atrial fib-
rillation) in patients with ConHD with increasing age
[16]. Other possible explanations include a general lack
of awareness and inadequate long-term care of adults
with ConHD in Taiwan. Taken together, medical care
problems and heart failure remain the most commonly
reported MACE in Taiwan in adults with ConHD. In-
creased efforts in public preventative healthcare are re-
quired to address these issues.
Among different types of ConHD, the incidence of
MACE was the highest in cyanotic ConHD patients,
followed up by PDA, ASD and VSD as KM curve shown
at Figure 3. Moreover, surgical correction helped to de-
creased MACE in the ConHD cohort (Table 4). The
adult patients with ASD benefited most from surgical
correction, with a reduction in the risk of MACE of up
to 66%. Attie et al reported that adult ASD patients
benefit from surgical correction with regards to overall
comorbidity events mainly in decreasing pneumonia but
not MACE [17]. To the best of our knowledge, this is
the first report to demonstrate that adult ASD patients
have a decreased risk of long-term MACE if they receive
surgical correction.
We further separated ConHD patients into short-term
and long-term follow up to demonstrate that the inci-
dence of MACE decreased with longer follow up time.
Another interesting finding as table 4 showed is that
those ConHD patients with surgical correction benefited
mostly within 3 years post-surgery follow up and this
surgical beneficial effect decreased afterward. The causes
of these time effects need to be investigated in the future
study.
In summary, the current study is the first to confirm
the increased long-term morbidity observed in adults
with ConHD in a large scale Asian-based population,
and the benefit of surgical correction in decreasing the
risk of MACE in those patients. These findings emphasize
the necessity of lifetime medical expertise as part of regu-
lar follow-up for adults with ConHD.
Because this is a population-based study from data-
base, there are some limitations. First, the environmental
and risk factors such as aging, smoking, obesity, and
metabolic syndrome were difficult to identify from the
database and could not be adjusted in the analysis. Sec-
ond, although the echocardiography data for application
of HV are essential, the exact detailed laboratory or
echocardiography information was inaccessible. There-
fore, this study reported the results from clinicallydiagnosed ConHD patients without the severity of the
disease. The may imply underestimation of the effects of
severe ConHD on MACE. However, the cyanotic ConHD
did show the highest MACE and mortality in this study as
previously discussed. In addition, surgical conditions in-
cluding perioperative risk, medical compliance and de-
tailed surgical procedures were difficult to elucidate based
on ICD-coded record system. A prospective study about
the surgical benefit under different surgical conditions
should be designed in the coming future.
Conclusions
After a median of 11 years of follow-up, the Taiwanese
patients with adult congenital heart disease were at an
increased risk of life-long cardiovascular MACE, includ-
ing heart failure, stroke, acute coronary syndrome, and
malignant dysrhythmia. Surgical correction may help to
decrease long-term MACE in ConHD patients, espe-
cially those with ASD.
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